Island Pharmaceuticals Limited (ASX:ILA)

Australia flag Australia · Delayed Price · Currency is AUD
0.4600
+0.0300 (6.98%)
At close: Jan 14, 2026
196.77%
Market Cap115.69M
Revenue (ttm)118.91K
Net Income (ttm)-3.92M
Shares Out269.05M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume222,224
Average Volume266,844
Open0.4500
Previous Close0.4300
Day's Range0.4400 - 0.4600
52-Week Range0.1200 - 0.6300
Beta0.21
RSI51.19
Earnings DateFeb 22, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol ILA
Full Company Profile

Financial Performance

In 2025, Island Pharmaceuticals's revenue was 118,910, a decrease of -90.57% compared to the previous year's 1.26 million. Losses were -3.92 million, 36.9% more than in 2024.

Financial Statements

News

There is no news available yet.